New Guidance Helps Clinicians Use Pemivibart to Protect Immunocompromised Patients From COVID-19

This Medical News story discusses new guidelines for the use of pemivibart, a monoclonal antibody marketed as Pemgarda, as preexposure prophylaxis against COVID-19 in immunocompromised individuals.

Authors

Publication Details

Journal
JAMA
Published
2024-09-13
DOI
https://doi.org/10.1001/jama.2024.18589
Citations
7
Primary Topic
Immune responses and vaccinations
Type
article
Field-Weighted Citation Impact
1.68
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

New Guidance Helps Clinicians Use Pemivibart to Protect Immunocompromised Patients From COVID-19

Anna Bock
7 citations
JAMA
Immune responses and vaccinations
1.68
article

New Guidance Helps Clinicians Use Pemivibart to Protect Immunocompromised Patients From COVID-19

Anna Bock
article en
7 citations

Abstract

This Medical News story discusses new guidelines for the use of pemivibart, a monoclonal antibody marketed as Pemgarda, as preexposure prophylaxis against COVID-19 in immunocompromised individuals.

JAMAVol. 332(14)
Good health and well-being
Openalex Percentile: Top 16%
Immune responses and vaccinations
1.68
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

New Guidance Helps Clinicians Use Pemivibart to Protect Immunocompromised Patients From COVID-19 — Anna Bock · JAMA (2024) | TGRS Research Map | TGRS